Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)

China flag China · Delayed Price · Currency is CNY
28.03
+0.07 (0.25%)
Aug 22, 2025, 2:45 PM CST
0.25%
Market Cap69.16B
Revenue (ttm)40.33B
Net Income (ttm)2.92B
Shares Out2.64B
EPS (ttm)1.10
PE Ratio25.59
Forward PE29.08
Dividend0.32 (1.14%)
Ex-Dividend DateAug 4, 2025
Volume25,250,143
Average Volume49,133,666
Open28.01
Previous Close27.96
Day's Range27.74 - 28.13
52-Week Range21.78 - 30.44
Beta0.67
RSI57.45
Earnings DateAug 27, 2025

About SHA:600196

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for oncology and immunomodulation, metabolism and digestive system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetologym personal care,... [Read more]

Sector Healthcare
Founded 1994
Employees 40,557
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600196
Full Company Profile

Financial Performance

In 2024, SHA:600196's revenue was 41.07 billion, a decrease of -0.80% compared to the previous year's 41.40 billion. Earnings were 2.77 billion, an increase of 16.13%.

Financial Statements

News

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.

2 years ago - Reuters

Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech

Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment

3 years ago - Forbes

Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal

Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen's Bavarian Nordic in a $225 million deal.

3 years ago - Seeking Alpha

China's health-care sector may be next to face regulatory crackdown, says economist

Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...

4 years ago - CNBC International TV

Pandemic Accelerates China's Drive Into mRNA Treatments

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese compan...

4 years ago - Seeking Alpha

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma...

4 years ago - Seeking Alpha

Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co...

4 years ago - Seeking Alpha

Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations

Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.

4 years ago - CNBC